# US 2015/0147336 A1 · Interferon alpha-induced pharmacodynamic markers and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147336 A1
- Document ID: US20150147336A1
- Status: Published application
- Kind: A1
- Application number: 14/606,832
- Filed: 2015-01-27
- Published: 2015-05-28
- Earliest claimed: 2010-02-17
- Assignees: Medlmmune, LLC
- Applicants: Medlmmune, LLC
- Inventors: Yihong YAO; Bahija Jallal; Ricardo Cibotti; Anthony Coyle; Peter Kiener
- Web page: https://patentgrep.com/patent/US20150147336A1

## CPC

- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/249: {Interferons}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

## Claims

### Claim at position 1

1-225. (canceled)

### Claim 226

A method for treating lupus, comprising:
administering an antibody, or antigen binding portion thereof, to a subject identified as having an increase in mRNA of
interferon-induced protein 44 (IFI44),
interferon alpha-inducible protein 6 (IFI6),
radical S-adenosyl methionine domain containing 2 (RSAD2),
interferon-induced protein 44-like (IFI44L) and
interferon alpha-inducible protein 27 (IFI27)
genes in a biological sample, thereby treating the lupus,
wherein the antibody, or antigen binding portion thereof, comprises:
(a) a heavy chain variable region CDR1 comprising SEQ ID NO: 3;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO: 4;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO: 5;
(d) a light chain variable region CDR1 comprising SEQ ID NO: 6;
(e) a light chain variable region CDR2 comprising SEQ ID NO: 7; and
(f) a light chain variable region CDR3 comprising SEQ ID NO: 8.

### Claim 227 (depends on 226)

The method of claim 226, wherein the antibody, or antigen binding portion thereof, comprises a heavy chain variable region comprising SEQ ID NO: 9 and a light chain variable region comprising SEQ ID NO: 10.

### Claim 228 (depends on 226)

The method of claim 226, wherein an antibody is administered to the subject and the antibody comprises:
(a) a heavy chain variable region CDR1 comprising SEQ ID NO: 3;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO: 4;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO: 5;
(d) a light chain variable region CDR1 comprising SEQ ID NO: 6;
(e) a light chain variable region CDR2 comprising SEQ ID NO: 7; and
(f) a light chain variable region CDR3 comprising SEQ ID NO: 8.

### Claim 229 (depends on 226)

The method of claim 226, wherein an antibody is administered to the subject and the antibody comprises a heavy chain variable region comprising SEQ ID NO: 9 and a light chain variable region comprising SEQ ID NO: 10.

### Claim 230 (depends on 226)

The method of claim 226, wherein the increase in the mRNA of the genes is an average increase in the mRNA of the genes.

### Claim 231 (depends on 230)

The method of claim 230, wherein the average increase is a mean increase or median increase.

### Claim 232 (depends on 226)

The method of claim 226, wherein the increase in the mRNA that has been detected for the sample is of genes consisting of IFI44, IFI6, RSAD2, IFI44L and IFI27.

### Claim 233 (depends on 228)

The method of claim 228, wherein the increase in the mRNA that has been detected for the sample is of genes consisting of IFI44, IFI6, RSAD2, IFI44L and IFI27.

### Claim 234 (depends on 229)

The method of claim 229, wherein the increase in the mRNA that has been detected for the sample is of genes consisting of IFI44, IFI6, RSAD2, IFI44L and IFI27.

### Claim 235 (depends on 226)

The method of claim 226, wherein the sample is whole blood or serum.

### Claim 236 (depends on 228)

The method of claim 228, wherein the sample is whole blood or serum.

### Claim 237 (depends on 229)

The method of claim 229, wherein the sample is whole blood or serum.

### Claim 238 (depends on 226)

The method of claim 226, wherein the subject is in need of treatment of systemic lupus erythematosus.

### Claim 239 (depends on 228)

The method of claim 228, wherein the subject is in need of treatment of systemic lupus erythematosus.

### Claim 240 (depends on 229)

The method of claim 229, wherein the subject is in need of treatment of systemic lupus erythematosus.

### Claim 241 (depends on 226)

The method of claim 226, which comprises detecting the mRNA levels of the genes in the sample from the subject.

### Claim 242 (depends on 241)

The method of claim 241, comprising:
(i) isolating RNA from the sample;
(ii) synthesizing cDNA from the RNA;
(iii) hybridizing the cDNA with oligonucleotides that hybridize to the polynucleotides, and
(iv) amplifying the cDNA and detecting the amplified products.

### Claim 243 (depends on 228)

The method of claim 228, which comprises detecting the mRNA levels of the genes in the sample from the subject.

### Claim 244 (depends on 243)

The method of claim 243, comprising:
(i) isolating RNA from the sample;
(ii) synthesizing cDNA from the RNA;
(iii) hybridizing the cDNA with oligonucleotides that hybridize to the polynucleotides, and
(iv) amplifying the cDNA and detecting the amplified products.
